APA
Coimbra S., Oliveira H., Neuparth M. J., Proença J. B., Figueiredo A., Rocha-Pereira P. & Santos-Silva A. (20161214). Systemic inflammation and proinflammatory interleukin-17 signalling persist at the end of therapy in patients with metabolic syndrome and psoriasis, reducing the length of remission. : The British journal of dermatology.
Chicago
Coimbra S, Oliveira H, Neuparth M J, Proença J B, Figueiredo A, Rocha-Pereira P and Santos-Silva A. 20161214. Systemic inflammation and proinflammatory interleukin-17 signalling persist at the end of therapy in patients with metabolic syndrome and psoriasis, reducing the length of remission. : The British journal of dermatology.
Harvard
Coimbra S., Oliveira H., Neuparth M. J., Proença J. B., Figueiredo A., Rocha-Pereira P. and Santos-Silva A. (20161214). Systemic inflammation and proinflammatory interleukin-17 signalling persist at the end of therapy in patients with metabolic syndrome and psoriasis, reducing the length of remission. : The British journal of dermatology.
MLA
Coimbra S, Oliveira H, Neuparth M J, Proença J B, Figueiredo A, Rocha-Pereira P and Santos-Silva A. Systemic inflammation and proinflammatory interleukin-17 signalling persist at the end of therapy in patients with metabolic syndrome and psoriasis, reducing the length of remission. : The British journal of dermatology. 20161214.